Research programme: apoptosis stimulants - OSI Pharmaceuticals

Drug Profile

Research programme: apoptosis stimulants - OSI Pharmaceuticals

Alternative Names: IGF-1R antagonists - OSI Pharmaceuticals; IGF-1R kinase inhibitors - OSI Pharmaceuticals; OSI 005

Latest Information Update: 07 Jul 2010

Price : $50

At a glance

  • Originator OSI Pharmaceuticals
  • Class Piperazines; Small molecules
  • Mechanism of Action Insulin-like growth factor I inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Jul 2010 Discontinued - Preclinical for Cancer in USA (PO)
  • 01 Apr 2006 Preclinical data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the Cancer pharmacodynamics section ,,,
  • 20 May 2004 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top